title: [Pancreas and islets of Langerhans transplantation: current status in 2009 and perspectives].
abstract: Type 1 diabetes currently affects 15,000 patients in Switzerland with a rising incidence worldwide. Pancreas or islet of Langerhans transplantation are alternatives to intensive insulin treatment, which decreases long-term complications at the cost of an increase of severe hyoglycemia. Pancreas transplantation, indicated mainly to diabetic patients with simultaneous kidney transplantation, has a high success rate, but is accompanied by high morbidity due to general surgery. Islet transplantation, a cell-therapy for type 1 diabetes, is in full development. It is mainly indicated as islet transplant alone in patients suffering from brittle diabetes, and is associated with a very low risk due to minimally invasive technique, but a lower rate of long-term success. New potential sources of beta cell replacement are beta-cell lines, stem cells and xenotransplantation.
authors: Laboratoire d'isolement et de transplantation cellulaire CMU, 1211 Genève 4.
authors: Nadja
authors: N
authors: Niclauss
authors: Philippe
authors: P
authors: Morel
authors: Francesco
authors: F
authors: Volonte
authors: Domenico
authors: D
authors: Bosco
authors: Thierry
authors: T
authors: Berney
mesh_terms: D003922:Diabetes Mellitus, Type 1 / Q000601:surgery*; D006801:Humans; D016381:Islets of Langerhans Transplantation; D016035:Pancreas Transplantation